Epratuzumab

Naked humanized antibody targeting CD22 receptors on B-lymphocytes.  Primary use is for the treatment of indolent and aggressive NHLs, and for autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjögren’s Syndrome.  Every year there are 56,000 newly diagnosed cases of NHL and 25,000 deaths.  SLE afflicts up to 1.4 million in the U.S.  In May 2006, epratuzumab was licensed to UCB, S.A. for all autoimmune disease indications worldwide.  A Phase IIb clinical trial for SLE is currently enrolling patients.  Additionally, there are three NCI-sponsored trials in oncology ongoing.

Veltuzumab

Naked humanized antibody targeting CD20 receptors on B-lymphocytes.  Primary use is for the treatment of NHL and autoimmune diseases.  Phase I/II trials for NHL have been fully enrolled.  New trials using the new subcutaneous formulation of veltuzumab for NHL and CLL patients and for ITP patients are on going.

Y-90 hPAM4

Yttrium-90-labeled humanized antibody targeting MUC1 expressing tumors.  There are more than 37,000 new cases and about 32,000 deaths each year from pancreatic cancer in the U.S.  A Phase I clinical trial has been completed.  A Phase Ib clinical trial to study fractionated radioimmunotherapy combined with chemotherapy is enrolling patients.

Milatuzumab

Naked humanized antibody targeting CD74 expressing tumors.  Primary use is for the treatment of multiple myeloma.  There are 14,000 new cases and 11,000 deaths every year related to multiple myeloma.  Phase I clinical trials in mutilple myeloma are ongoing. Studies in NHL/CLL are open to enrollment.

Yttrium Y-90 Epratuzumab Tetraxetan

Yttrium-90-labeled humanized antibody targeting CD22 receptors on B-cell lymphomas.  Primary use is for the treatment of indolent and aggressive NHLs.  Every year there are 56,000 newly diagnosed cases and 25,000 deaths.  Phase I/II clinical trials have been completed. Additional studies are underway.

Radiolabeled Labetuzumab

Radiolabeled humanized antibody targeting CEA-expressing tumors.  Primarily use for the treatment of inoperable metastatic solid tumors.  Every year there are 140,000 newly diagnosed and 65,000 deaths due to colorectal cancer; 180,000 new cases and 45,000 deaths due to breast cancer; 172,000 new case and 160,000 deaths due to lung cancer; 25,000 new case and 15,000 deaths due to ovarian cancer; and 29,000 new cases and 28,000 deaths due to pancreatic cancer.  Phase I clinical trials of yttrium-90-labeled labetuzumab have been completed as well as Phase II clinical trials of iodine-131-labeled labetuzumab for the treatment of patients with colorectal cancer that has metastasized to the liver.

Milatuzumab-Dox

Doxorubicin conjugated humanized antibody targeting CD74 expressing tumors.  Primary use is for the treatment of multiple myeloma, NHL and chronic lymphocytic leukemia. 

RNAse-Conjugate

Inactivation-resistant RNAse conjugated to humanized antibody, using internalizing tumor antibodies.  Primary use is for NHL and solid-tumor anticancer therapy.  It is currently in preclinical development.

DNL Constructs of Antibody, Antibody-Drug Conjugate and Interferon-Alpha

New multivalent monospecific and bispecific antibodies, antibody-drug conjugates and non-antibody based protein constructs were created using the Dock-and-Lock platform technology for potential cancer therapy.  The program is currently in preclinical research.

Dendritic Cell Vaccine

Tumor antigen conjugated to internalizing, dendritic cell-targeting antibody.  Primary use may be as a tumor vaccine.  It is in preclinical research.